Search

Your search keyword '"Chinot, O."' showing total 42 results

Search Constraints

Start Over You searched for: Author "Chinot, O." Remove constraint Author: "Chinot, O." Publisher oxford university press (oup) Remove constraint Publisher: oxford university press (oup)
42 results on '"Chinot, O."'

Search Results

4. P04.08 Biopsy-only glioblastoma (BO-GBM) as a heterogeneous group of patients

5. PL03.1.A Surgery for glioblastomas in the elderly: an ANOCEF trial (CSA)

6. KS02.4.A Olaparib in Recurrent IDH-mutant High-Grade Glioma (OLAGLI)

7. P11.04 Autonomy duration as analyzed by KPS≥70 cumulative time in patients with biopsy-only glioblastoma (BO-GBM). A sub-analysis of the Timone cohort

8. PL03.4.A Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period

9. OS7.4 Calculating the net clinical benefit in brain tumor clinical trials by combining survival and health-related quality of life data using two methods: quality adjusted survival effect sizes (QASES) and joint modelling (JM)

10. OS7.2 Measuring change in health-related quality of life: the added value of analysis on the individual patient level in glioma patients in clinical decision making

11. OS4.1 MEVITEM: A European, randomized, open-label, Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma presenting an activation of the Sonic Hedgehog (SHH) pathway

12. P14.73 Toxicity and outcomes of reduced-dose whole brain radiotherapy as consolidation treatment for patients with CNS lymphoma in real life setting

19. OS2.4 Angiotensin II Receptor Blockers, steroids and radiotherapy in glioblastoma - A randomized multicenter trial (ASTER Trial). An ANOCEF Study

20. Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial

23. P20.01 MEVITEM: A European, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma presenting an activation of the Sonic Hedgehog pathway

26. AT-17 * RE-ANALYSIS OF PFS/RESPONSE USING ORIGINAL MACDONALD CRITERIA AND RESPONSE EVALUATION CRITERIA IN SOLID TUMORS IN THE PHASE III AVAGLIO STUDY OF BEVACIZUMAB PLUS RADIOTHERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA

27. ET-12 * PHASE II STUDY OF ONARTUZUMAB PLUS BEVACIZUMAB VERSUS PLACEBO PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

28. AT-18 * SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM])

30. AI-29 * ANGIOGENIC SWITCH FROM VEGFR2/HIF1 IN NEWLY DIAGNOSED GLIOBLASTOMA (GB) TO CXCR4-SDF1 PATHWAY IN RECURRENT PAIRED TUMOR AFTER RADIOTHERAPY (RT)-TEMOZOLOMIDE (TMZ)

32. BI-22 * CORRELATION OF MOLECULAR SUBTYPES WITH OVERALL SURVIVAL (OS) IN AVAGLIO, A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB (BEV) PLUS RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)

39. Ongoing Clinical Trials

41. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study

Catalog

Books, media, physical & digital resources